157 related articles for article (PubMed ID: 32526764)
21. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy in the treatment of ovarian carcinosarcoma].
Melilli GA; Di Vagno G; Cormio G; Greco P; Fontana A; Carriero C; Loverro G; Selvaggi L
Minerva Ginecol; 1999 Nov; 51(11):445-8. PubMed ID: 10726444
[TBL] [Abstract][Full Text] [Related]
23. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA; Filiaci VL; Hensley ML; Huang HQ; Moore KN; Tewari KS; Copeland LJ; Secord AA; Mutch DG; Santin A; Warshal DP; Spirtos NM; DiSilvestro PA; Ioffe OB; Miller DS
J Clin Oncol; 2022 Mar; 40(9):968-977. PubMed ID: 35007153
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Toyoshima M; Akahira J; Matsunaga G; Niikura H; Ito K; Yaegashi N; Tase T
Gynecol Oncol; 2004 Sep; 94(3):774-8. PubMed ID: 15350372
[TBL] [Abstract][Full Text] [Related]
25. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
26. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
27. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
Campos SM; Brady WE; Moxley KM; O'Cearbhaill RE; Lee PS; DiSilvestro PA; Rotmensch J; Rose PG; Thaker PH; O'Malley DM; Hanjani P; Zuna RE; Hensley ML
Gynecol Oncol; 2014 Jun; 133(3):537-41. PubMed ID: 24594074
[TBL] [Abstract][Full Text] [Related]
29. Carcinosarcoma of the ovary: a case-control study.
Rauh-Hain JA; Growdon WB; Rodriguez N; Goodman AK; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
Gynecol Oncol; 2011 Jun; 121(3):477-81. PubMed ID: 21420726
[TBL] [Abstract][Full Text] [Related]
30. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
31. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
Temkin SM; Hellmann M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
[TBL] [Abstract][Full Text] [Related]
32. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MMK; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Dec; 147(3):565-571. PubMed ID: 29056442
[TBL] [Abstract][Full Text] [Related]
33. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine.
Simon SR; Wang SE; Uhl M; Shackney S
Gynecol Oncol; 1991 May; 41(2):161-6. PubMed ID: 2050307
[TBL] [Abstract][Full Text] [Related]
34. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
36. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
[TBL] [Abstract][Full Text] [Related]
37. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
38. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
39. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
[TBL] [Abstract][Full Text] [Related]
40. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
